Publish with Us Search
Publish with Us

Targeted Cancer Therapy Connect

ISSN: 3105-3629

Eyad Elkord
Editor-in-Chief

Eyad Elkord
Editor-in-Chief

View Profile

Targeted Cancer Therapy Connect is a peer-reviewed, open-access journal dedicated to advancing precision and targeted approaches in cancer treatment. The journal publishes innovative research that deepens understanding of the molecular and immunological mechanisms driving cancer progression and therapeutic response.

Volumes 2
Articles 12
Volume: 2, 2026
Submit Article Join Our Editorial Board Become a Reviewer
Download Flyer
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Open Access Policy:
All articles published in the journal Targeted Cancer Therapy Connect are Gold Open Access, immediately available without any embargo period, and licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license. This license facilitates the unrestricted dissemination of articles, encouraging widespread sharing and utilization of valuable research contributions.

Publication Frequency:
Targeted Cancer Therapy Connect follows a continuous publication model and is licensed under Creative Commons Attribution 4.0 (CC BY 4.0).

Publication Charges:
There will be no article processing charges (APCs) for submissions made by December 31, 2026, and all articles will be published as Open Access. Furthermore, the journal does not levy any additional fees on authors, including editorial processing charges, language editing fees, colour charges, submission fees, membership fees, or any other supplementary charges.

Subject Categories:
Targeted Cancer Therapy, Immunotherapy, Precision Oncology

Article Template:

You are encouraged to use the template to format your article according to our guidelines. However, this is not mandatory, as our layout team will ensure all necessary adjustments are made after acceptance and prior to final publication.

Download Template 

Target Audience:
Targeted Cancer Therapy Connect provides a platform for researchers, clinicians, and industry experts to share insights, foster collaboration, and explore emerging directions in targeted and immune-based cancer treatment.

Ethics Statement:

All articles published by Targeted Cancer Therapy Connect adhere strictly to the ethical guidelines suggested by the Committee on Publication Ethics (COPE). We execute a stringent peer-review procedure that meticulously assesses the originality, quality, and precision of the research we disseminate. We employ advanced tools to scrutinize the legitimacy of submitted content and maintain a firm zero-tolerance stance toward instances of plagiarism, data manipulation, or inappropriate authorship. For further details, please review our comprehensive Editorial Policies & Ethical Oversight.

Insights

More Insights

18 Days

Time to First Peer Review Decision

24 Days

Time to Final Acceptance

5 Days

Acceptance to First Online

Recent Updates

All Updates
Welcoming Dr. Eyad Elkord to Cancer Immunology Connect
2024-08-19
Announcing the Launch of Cancer Immunology Connect
2024-08-15

Recent Articles

All Articles
open-access Research Article

Available Online: 02 Feb 2026

Association of 12q21.32 cn‑LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia

Volume 2

https://doi.org/10.69709/TCTC.2026.199772
open-access Review Article

Available Online: 26 Jan 2026

Here, there, and Everywhere: Alpha-fetoprotein in Cancer Immunotherapy

Volume 2

https://doi.org/10.69709/TCTC.2025.121204
open-access Editorial

Published: 30 Dec 2025

Preface

Volume 1

It is my honor as Editor-in-Chief to present the first volume of Targeted Cancer Therapy Connect, a new peer-reviewed journal focused on the rapidly advancing fields of cancer immunology and immunotherapy. The aim of this first volume and of subsequent publications is to deepen our understanding of the molecular and cellular drivers of cancer and to highlight strategies that selectively..

https://doi.org/10.69709/CIConnect.2025.107012
open-access Mini-Review

Published: 31 Dec 2025

Covalent BH3-Mimetics and PROTACs: Targeting BCL2 Family for Precision Apoptosis Induction

Volume 1

The BCL2 family of proteins serves as a central regulator of mitochondrial outer membrane permeabilization (MOMP) and intrinsic apoptosis, with anti-apoptotic members such as BCL2, BCL-XL, and MCL1 frequently overexpressed in many cancers to evade programmed cell death. Traditional BH3 mimetics, such as venetoclax and navitoclax, have revolutionized the treatment of hematologic malignancies by competitively inhibiting these pro-survival proteins. Yet,..

https://doi.org/10.69709/TCTC.2025.133129
Share
Help